TABLE 67Maintenance efficacy assumptions

Costs (£)QALYsCER vs SCICERs
MeanSDMeanSD
MNT relapse = ¼ cs_relapse
SC14,2073010.80280.0419Baseline
Infliximab IND15,0104240.88240.0766£10,126 per QALY£10,126 per QALY
Infliximab MNT19,6871950.89110.0808£62,061 per QALY£537,241 per QALY
SC14,2073010.80280.0419Dominates
Adalimumab IND84924350.88240.0765DominatesBaseline
Adalimumab MNT14,4012120.89180.0806£2,180 per QALY£628,617 per QALY
MNT relapse = ⅛ cs_relapse
SC14,2073010.80280.0419Baseline
Infliximab IND15,0104240.88240.0766£10,126 per QALY£10,126 per QALY
Infliximab MNT19,4381980.89540.0820£57,674 per QALY£398,649 per QALY
SC14,2073010.80280.0419Dominates
Adalimumab IND84924350.88240.0765DominatesBaseline
Adalimumab MNT14,2532100.89350.812£507 per QALY£519,000 per QALY
MNT relapse = 1/16 cs_relapse
SC14,2073010.80280.0419Baseline
Infliximab IND15,0104240.88240.0766£10,126 per QALY£10,126 per QALY
Infliximab MNT19,3112000.89400.0819£55,119 per QALY£330,615 per QALY
SC14,2073010.80280.0419Dominates
Adalimumab IND84924350.88240.0765DominatesBaseline
Adalimumab MNT14,1802070.89380.0799Dominates£498,947 per QALY

CER, cost-effectiveness ratio.

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.